Chemistfrog
Long only, growth, momentum, contrarian

Recent GBM Drug Failures Could Turn Large Pharma Attention To DelMar Pharmaceuticals

Genentech's June 2nd, 2013 announcement that its blockbuster drug, Avastin (bevacizumab), failed to prolong life in newly-diagnosed glioblastoma multiforme (GBM) patients was a sharp reminder of the severity of the disease and the real need for solid hope for patients battling the dreaded brain cancer. With U.S. incidence of 2 to 3 persons per 100,000 annually diagnosed with GBM, prognosis is currently poor with a median survival rate of 15 months and a 5 year survival rate of just 4%. Current treatment options are limited with U.S. approvals limited to Temozolomide, approved in 2005 for newly-diagnosed GBM; Avastin, approved in 2009 for recurrent and previously-treated GBM; Prolifeprosan 20 with Carmustine Implant, approved in 1997 as part of the initial treatment...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details